Genetic demonstration of intestinal NPC1L1 as a major determinant of hepatic cholesterol and blood atherogenic lipoprotein levels

Atherosclerosis

Volumn 237, Issue 2, 2014, Pages 609-617

  Xie, Ping ^a,b   Zhu, Hongling ^c   Jia, Lin ^a   Ma, Yinyan ^a,c   Tang, Weiqing ^c   Wang, Youlin ^c   Xue, Bingzhong ^d   Shi, Hang ^d   Yu, Liqing ^a,c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

^c UNIVERSITY OF MARYLAND   (United States)

^d GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Apolipoprotein B; Cholesterol absorption; Chylomicron remnant; Fecal neutral sterol excretion; Low density lipoprotein receptor; Niemann Pick C1 Like 1

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL; COMPLEMENTARY DNA; EZETIMIBE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; NIEMANN PICK C1 LIKE 1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; APOB PROTEIN, MOUSE; APOLIPOPROTEIN B; APOLIPOPROTEIN B48; AZETIDINE DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEMBRANE PROTEIN; NPC1L1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; EMBRYO; FEMALE; GASTROINTESTINAL TRACT; HUMAN; HUMAN TISSUE; INTESTINE ABSORPTION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SECRETION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN EXPRESSION; TRANSGENE; ANIMAL; BLOOD; C57BL MOUSE; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; HOMEOSTASIS; INTESTINE; KNOCKOUT MOUSE; LIVER; MALE; METABOLISM;

ANIMALS; APOLIPOPROTEIN B-48; APOLIPOPROTEINS B; AZETIDINES; CHOLESTEROL; CHOLESTEROL, LDL; EZETIMIBE; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; INTESTINES; LIVER; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; PHENOTYPE; RECEPTORS, LDL; TRANSGENES;

EID: 84910068238     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.09.036     Document Type: Article

References (49)

1. Wilson P.W., Garrison R.J., Castelli W.P., Feinleib M., McNamara P.M., Kannel W.B. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am. J. Cardiol. 1980, 46(4):649-654.
2. Dietschy J.M., Turley S.D., Spady D.K. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J.Lipid Res. 1993, 34(10):1637-1659.
3. Van Heek M., France C.F., Compton D.S., McLeod R.L., Yumibe N.P., Alton K.B., Sybertz E.J., Davis H.R. Invivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J.Pharmacol. Exp. Ther. 1997, 283(1):157-163.
4. Brown M.S., Faust J.R., Goldstein J.L. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J.Biol. Chem. 1978, 253(4):1121-1128.
5. Bays H.E., Moore P.B., Drehobl M.A., Rosenblatt S., Toth P.D., Dujovne C.A., Knopp R.H., Lipka L.J., Lebeaut A.P., Yang B., et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin. Ther. 2001, 23(8):1209-1230.
6. Davies J.P., Levy B., Ioannou Y.A. Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L1. Genomics 2000, 65(2):137-145.
7. Altmann S.W., Davis H.R., Zhu L.J., Yao X., Hoos L.M., Tetzloff G., Iyer S.P., Maguire M., Golovko A., Zeng M., et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303(5661):1201-1204.
8. Garcia-Calvo M., Lisnock J., Bull H.G., Hawes B.E., Burnett D.A., Braun M.P., Crona J.H., Davis H.R., Dean D.C., Detmers P.A., et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. U. S. A. 2005, 102(23):8132-8137.
9. Weinglass A.B., Kohler M., Schulte U., Liu J., Nketiah E.O., Thomas A., Schmalhofer W., Williams B., Bildl W., McMasters D.R., et al. Extracellular loop C of NPC1L1 is important for binding to ezetimibe. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(32):11140-11145.
10. Yu L., Bharadwaj S., Brown J.M., Ma Y., Du W., Davis M.A., Michaely P., Liu P., Willingham M.C., Rudel L.L. Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. J.Biol. Chem. 2006, 281(10):6616-6624.
11. Temel R.E., Tang W., Ma Y., Rudel L.L., Willingham M.C., Ioannou Y.A., Davies J.P., Nilsson L.M., Yu L. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J.Clin. Invest. 2007, 117(7):1968-1978.
12. Tang W., Ma Y., Yu L. Plasma cholesterol is hyperresponsive to statin in ABCG5/ABCG8 transgenic mice. Hepatology 2006, 44(5):1259-1266.
13. Davies J.P., Scott C., Oishi K., Liapis A., Ioannou Y.A. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J.Biol. Chem. 2005, 280(13):12710-12720.
14. Davis H.R., Zhu L.J., Hoos L.M., Tetzloff G., Maguire M., Liu J., Yao X., Iyer S.P., Lam M.H., Lund E.G., et al. Niemann-Pick C1 like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J.Biol. Chem. 2004, 279(32):33586-33592.
15. Jia L., Ma Y., Rong S., Betters J.L., Xie P., Chung S., Wang N., Tang W., Yu L. Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis. J.Lipid Res. 2010, 51(11):3135-3144.
16. Jia L., Ma Y., Liu G., Yu L. Dietary cholesterol reverses resistance to diet-induced weight gain in mice lacking Niemann-Pick C1-Like 1. J.Lipid Res. 2010, 51(10):3024-3033.
17. Labonte E.D., Camarota L.M., Rojas J.C., Jandacek R.J., Gilham D.E., Davies J.P., Ioannou Y.A., Tso P., Hui D.Y., Howles P.N. Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295(4):G776-G783.
18. Davis H.R., Hoos L.M., Tetzloff G., Maguire M., Zhu L.J., Graziano M.P., Altmann S.W. Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE-/- mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27(4):841-849.
19. Kesaniemi Y.A., Miettinen T.A. Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur. J. Clin. Invest. 1987, 17(5):391-395.
20. Cohen J.C., Pertsemlidis A., Fahmi S., Esmail S., Vega G.L., Grundy S.M., Hobbs H.H. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(6):1810-1815.
21. Bosner M.S., Lange L.G., Stenson W.F., Ostlund R.E. Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J.Lipid Res. 1999, 40(2):302-308.
22. Sehayek E., Nath C., Heinemann T., McGee M., Seidman C.E., Samuel P., Breslow J.L. U-shape relationship between change in dietary cholesterol absorption and plasma lipoprotein responsiveness and evidence for extreme interindividual variation in dietary cholesterol absorption in humans. J.Lipid Res. 1998, 39(12):2415-2422.
23. Madison B.B., Dunbar L., Qiao X.T., Braunstein K., Braunstein E., Gumucio D.L. Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J.Biol. Chem. 2002, 277(36):33275-33283.
24. Garber D.W., Kulkarni K.R., Anantharamaiah G.M. Asensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samples. J.Lipid Res. 2000, 41(6):1020-1026.
25. Siri P., Candela N., Zhang Y.L., Ko C., Eusufzai S., Ginsberg H.N., Huang L.S. Post-transcriptional stimulation of the assembly and secretion of triglyceride-rich apolipoprotein B lipoproteins in a mouse with selective deficiency of brown adipose tissue, obesity, and insulin resistance. J.Biol. Chem. 2001, 276(49):46064-46072.
26. Li G., Hernandez-Ono A., Crooke R.M., Graham M.J., Ginsberg H.N. Effects of antisense-mediated inhibition of 11beta-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism. J.Lipid Res. 2011, 52(5):971-981.
27. Valasek M.A., Weng J., Shaul P.W., Anderson R.G., Repa J.J. Caveolin-1 is not required for murine intestinal cholesterol transport. J.Biol. Chem. 2005, 280(30):28103-28109.
28. Roth S., Franken P., van Veelen W., Blonden L., Raghoebir L., Beverloo B., van Drunen E., Kuipers E.J., Rottier R., Fodde R., et al. Generation of a tightly regulated doxycycline-inducible model for studying mouse intestinal biology. Genesis 2009, 47(1):7-13.
29. Repa J.J., Turley S.D., Lobaccaro J.A., Medina J., Li L., Lustig K., Shan B., Heyman R.A., Dietschy J.M., Mangelsdorf D.J. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000, 289(5484):1524-1529.
30. Rashid S., Curtis D.E., Garuti R., Anderson N.N., Bashmakov Y., Ho Y.K., Hammer R.E., Moon Y.A., Horton J.D. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(15):5374-5379.
31. Grundy S.M. Absorption and metabolism of dietary cholesterol. Annu. Rev. Nutr. 1983, 3:71-96.
32. Yu L., Hammer R.E., Li-Hawkins J., Von Bergmann K., Lutjohann D., Cohen J.C., Hobbs H.H. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(25):16237-16242.
33. Yu L., Li-Hawkins J., Hammer R.E., Berge K.E., Horton J.D., Cohen J.C., Hobbs H.H. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J.Clin. Invest. 2002, 110(5):671-680.
34. Graf G.A., Li W.P., Gerard R.D., Gelissen I., White A., Cohen J.C., Hobbs H.H. Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. J.Clin. Invest. 2002, 110(5):659-669.
35. Davis H.R., Compton D.S., Hoos L., Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler. Thromb. Vasc. Biol. 2001, 21(12):2032-2038.
36. Davis H.R., Lowe R.S., Neff D.R. Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis 2011, 215(2):266-278.
37. Repa J.J., Turley S.D., Quan G., Dietschy J.M. Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption. J.Lipid Res. 2005, 46(4):779-789.
38. Gagne C., Gaudet D., Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002, 105(21):2469-2475.
39. Wang D.Q. Regulation of intestinal cholesterol absorption. Annu. Rev. Physiol. 2007, 69:221-248.
40. Xie C., Zhou Z.S., Li N., Bian Y., Wang Y.J., Wang L.J., Li B.L., Song B.L. Ezetimibe blocks the internalization of NPC1L1 and cholesterol in mouse small intestine. J.Lipid Res. 2012, 53(10):2092-2101.
41. Rudel L.L., Lee R.G., Cockman T.L. Acyl coenzyme A: cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis. Curr. Opin. Lipidol. 2001, 12(2):121-127.
42. Xie C., Woollett L.A., Turley S.D., Dietschy J.M. Fatty acids differentially regulate hepatic cholesteryl ester formation and incorporation into lipoproteins in the liver of the mouse. J.Lipid Res. 2002, 43(9):1508-1519.
43. Telford D.E., Sutherland B.G., Edwards J.Y., Andrews J.D., Barrett P.H., Huff M.W. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J.Lipid Res. 2007, 48(3):699-708.
44. Greeve J., Altkemper I., Dieterich J.H., Greten H., Windler E. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J.Lipid Res. 1993, 34(8):1367-1383.
45. Warnakula S., Hsieh J., Adeli K., Hussain M.M., Tso P., Proctor S.D. New insights into how the intestine can regulate lipid homeostasis and impact vascular disease: frontiers for new pharmaceutical therapies to lower cardiovascular disease risk. Can. J. Cardiol. 2011, 27(2):183-191.
46. Phillips C., Murugasu G., Owens D., Collins P., Johnson A., Tomkin G.H. Improved metabolic control reduces the number of postprandial apolipoprotein B-48-containing particles in type 2 diabetes. Atherosclerosis 2000, 148(2):283-291.
47. Mamo J.C., Watts G.F., Barrett P.H., Smith D., James A.P., Pal S. Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression?. Am. J. Physiol. Endocrinol. Metabol. 2001, 281(3):E626-E632.
48. Adeli K., Lewis G.F. Intestinal lipoprotein overproduction in insulin-resistant states. Curr. Opin. Lipidol. 2008, 19(3):221-228.
49. Su J.W., Lambert J.E., Clandinin M.T., Proctor S.D. Impaired postprandial metabolism of apolipoprotein B48-containing remnant particles in normolipidemic subjects with brittle type 1 diabetes. Diabetes Care 2009, 32(2):e21.